Technology
NVAC will facilitate the translational efforts of NIVI by providing industry-level expertise in vaccine development and conducting the early clinical testing of our vaccine candidates.
First-in-class
Bridging research, translational sciences, and development
NVAC will catalyse progress towards achieving the NIVI mission by enabling access to cutting-edge technologies and data-driven approaches to design, test, and optimise novel vaccine candidates. NVAC provides capabilities and expertise – either directly, or via external strategic partnerships – to bridge exploratory research and clinical (Phase 1 & 2, including CHIM) translational development.
NVAC will catalyse progress towards achieving the NIVI mission by enabling access to cutting-edge technologies and data-driven approaches to design, test, and optimise novel vaccine candidates. NVAC provides capabilities and expertise – either directly, or via external strategic partnerships – to bridge exploratory research and clinical (Phase 1 & 2, including CHIM) translational development.
NVAC will catalyse progress towards achieving the NIVI mission by enabling access to cutting-edge technologies and data-driven approaches to design, test, and optimise novel vaccine candidates. NVAC provides capabilities and expertise – either directly, or via external strategic partnerships – to bridge exploratory research and clinical (Phase 1 & 2, including CHIM) translational development.
Developing vaccines for a better future
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
NIVI will require a broad portfolio of diverse vaccine platforms, as well as ensure access to a state-of-the-art ‘adjuvant toolbox’ through dedicated strategic partnerships.
Introduction to pipeline
Bridging research, translational sciences, and development
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut meet the team.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore.
Contact
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore.
